EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway

Karim H Saba iD, Valeria Difilippo, Michal Kovac, Louise Cornmark, Linda Magnusson, Jenny Nilsson, Hilda van den Bos, Diana Cj Spierings, Mahtab Bidgoli, Tord Jonson, Vaiyapuri P Sumathi, Otte Brosjö and 6 more

The Journal of Pathology · 2024

DOI: 10.1002/path.6219 ↗

At a glance

Journal article in The Journal of Pathology, 2024. Written by Karim H Saba and 17 co-authors. Institution: Department of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden. Major MEDLINE topics: Osteosarcoma, Bone Neoplasms. Cited 24 times so far (Crossref); 84 references. The full text is freely available (open access, CC BY 4.0). Funded by: Swiss National Science Foundation, Barncancerfonden, Cancerfonden.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

TP53 is the most frequently mutated gene in human cancer. This gene shows not only loss‐of‐function mutations but also recurrent missense mutations with gain‐of‐function activity. We have studied the primary bone malignancy osteosarcoma, which harbours one of the most rearranged genomes of all cancers. This is odd since it primarily affects children and adolescents who have not lived the long life thought necessary to accumulate massive numbers of mutations. In osteosarcoma, TP53 is often disrupted by structural variants. Here, we show through combined whole‐genome and transcriptome analyses of 148 osteosarcomas that TP53 structural variants commonly result in loss of coding parts of the gene while simultaneously preserving and relocating the promoter region. The transferred TP53 promoter region is fused to genes previously implicated in cancer development. Paradoxically, these erroneously upregulated genes are significantly associated with the TP53 signalling pathway itself. This suggests that while the classical tumour suppressor activities of TP53 are lost, certain parts of the TP53 signalling pathway that are necessary for cancer cell survival and proliferation are retained. In line with this, our data suggest that transposition of the TP53 promoter is an early event that allows for a new normal state of genome‐wide rearrangements in osteosarcoma. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

OsteosarcomaBone NeoplasmsChildAdolescentHumansGenes, p53MutationPromoter Regions, GeneticGene FusionTumor Suppressor Protein p53

Author keywords

TP53 intron 1TP53 mutationTP53 promoterTP53 signalling pathwaygene fusionosteosarcomap53promoter swappingseparation-of-function mutation

Substances

Tumor Suppressor Protein p53TP53 protein, human

Authors and institutions

  • Department of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden.
  • Bone Tumour Reference Centre at the Institute of Pathology, University Hospital and University of Basel, Basel, Switzerland.
  • Faculty of Informatics and Information Technologies, Slovak University of Technology, Bratislava, Slovakia.
  • European Research Institute for the Biology of Ageing, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
  • Department of Clinical Genetics and Pathology, Laboratory Medicine, Medical Services, Skåne University Hospital, Lund, Sweden.
  • Department of Musculoskeletal Pathology, Royal Orthopaedic Hospital, Birmingham, UK.

ORCID profiles: Karim H Saba, Karolin H Nord

Funding

  • Swiss National Science Foundation
  • Barncancerfonden
  • Cancerfonden
  • Royal Swedish Academy of Sciences
  • Vetenskapsrådet
  • Lunds Universitet
  • Åke Wiberg Stiftelse
  • Kungliga Fysiografiska Sällskapet i Lund

Cite

APA

Saba, K. H., Difilippo, V., Kovac, M., Cornmark, L., Magnusson, L., Nilsson, J., van den Bos, H., Spierings, D. C., Bidgoli, M., Jonson, T., Sumathi, V. P., Brosjö, O., Staaf, J., Foijer, F., Styring, E., Nathrath, M., Baumhoer, D., & Nord, K. H. (2024). Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway. The Journal of Pathology. https://doi.org/10.1002/path.6219

Vancouver

Saba KH, Difilippo V, Kovac M, Cornmark L, Magnusson L, Nilsson J, et al. Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway. The Journal of Pathology. 2024. doi:10.1002/path.6219

BibTeX
@article{Saba2024,
  author = {Saba, Karim H and Difilippo, Valeria and Kovac, Michal and Cornmark, Louise and Magnusson, Linda and Nilsson, Jenny and van den Bos, Hilda and Spierings, Diana Cj and Bidgoli, Mahtab and Jonson, Tord and Sumathi, Vaiyapuri P and Brosjö, Otte and Staaf, Johan and Foijer, Floris and Styring, Emelie and Nathrath, Michaela and Baumhoer, Daniel and Nord, Karolin H},
  title = {Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway},
  journal = {The Journal of Pathology},
  year = {2024},
  doi = {10.1002/path.6219}
}
Start for free →